Cut price Herceptin and MabThera in India could set Roche's emerging market strategy
This article was originally published in Scrip
Roche will be partnering up with the Indian firm Emcure to launch reduced price versions of its anticancers Herceptin (trastuzumab) and MabThera (rituximab) in India. The move has nothing to do with India's decision to issue a compulsory license for Bayer's anticancer, Nexavar (sorafenib tosylate), but is instead more of a pilot for reaching lower income patients in emerging markets, the firm told Scrip.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.